Shift of Glucose Peak Time During Oral Glucose Tolerance Test is Associated with Changes in Insulin Secretion and Insulin Sensitivity After Therapy with Antidiabetic Drugs in Patients with Type?2 Diabetes

摘要

IntroductionDelay in peak blood glucose during an oral glucose tolerance test (OGTT) predicts declining β-cell function and poor ability to regulate glucose metabolism. Glucose peak time has not been used as a comparative indicator of the improvement in islet function after treatment with exenatide, insulin, or oral antidiabetic drugs (OADs). We evaluated the efficacy of three types of antidiabetic drugs on the basis of blood glucose peak time in patients with non-newly diagnosed type?2 diabetes.MethodsThe data from 100 patients with diabetes who completed two OGTTs within 6?months were collected. Thirty-seven of them with type?2 diabetes were treated with Humalog Mix25, 28 patients with OADs (metformin, acarbose, and gliclazide), and 35 patients with exenatide.ResultsGlycated hemoglobin improved in all three groups after treatment ( P ?0.05). Subcutaneous adipose tissue ( P ?0.01) and visceral adipose tissue ( P ?0.0001) significantly decreased in the exenatide group. The insulinogenic index (IGI) ( P =?0.01) and IGI?×?oral glucose insulin sensitivity (OGIS) ( P =?0.01) improved in the exenatide group only. Homeostatic assessment of β-cell function (HOMA-β) and OGIS were greater in the exenatide and OAD groups than in the Humalog Mix25 group (all P ?0.05). A shift to an earlier peak was observed in 57.1%, 35.7%, and 27.0% of patients in the exenatide, OAD, and Humalog Mix25 groups, respectively ( P =?0.029). OGIS (odds ratio [OR] 0.54, 95% confidence interval [CI] 0.33–0.89, P =?0.026) and IGI?×?OGIS (OR 1.72, 95% CI 0.44–6.68, P =?0.012) were independently related to shifts in glucose peak time.ConclusionExenatide, Humalog Mix25, and OADs improved glycemic metabolism. However, exenatide exhibited superior efficacy in shifting blood glucose peak time to an earlier point, while it improved insulin secretion and insulin sensitivity. Hence, the shift of glucose peak time may be considered an indicator for the evaluation of the effect of hypoglycemic drugs.